Taysha Gene Therapies (TSHA) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Taysha Gene Therapies (TSHA) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Taysha Gene Therapies

· TSHA

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

1.626 B

-2.40%

General

Market Cap: $1.63B
Enterprise Value: $1.16B
Shares Outstanding: 319,780,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 83.96%
Operating Margin: -2792.32%
Net Profit Margin: -2728.04%
FCF Margin: -2471.69%
ROA: -31.81%
ROE: -56.19%
ROIC: -34.46%
Current Ratio: 17.76
Debt-to-Equity: 0.14
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: -0.55
P/S: 284.00
P/FCF: —
P/B: 4.02
EV/EBITDA: -7.78

Growth

Rev 1Y: 17.28%
Rev 1Y Fwd Est: -80.47%
Rev 3Y (CAGR): 57.49%
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —

Income Statement (TTM)

Revenue: $5.49M
Gross Margin: 83.96%
Operating Expenses: $157.76M
Operating Income: -$153.16M
Net Profit: -$149.63M

Balance Sheet

EPS 5Y (CAGR)

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $455.41M
Working Capital: $435.46M
Total Assets: $470.43M
Net Debt: -$399.86M
Total Liabilities: $83.17M
Total Equity: $387.27M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$132.19M
Cash Flow from Investing: -$3.32M
Cash Flow from Financing: $275.72M
Free Cash Flow: -$135.57M
Capital Expenditures: $3.38M